|
시장보고서
상품코드
1983140
주기성 발열(PF) 시장 : 질환 유형별, 치료 유형별, 투여 경로별, 진단 유형별, 환자 그룹별, 최종사용자별, 유통 채널별, 지역별Periodic Fever Market, By Disease Type, By Treatment Type, By Route of Administration, By Diagnosis Type, By Patient Group, By End User, By Distribution Channel, By Geography |
||||||
주기성 발열(PF) 시장은 2026년에 7억 2,460만 달러로 추정되며, 2033년까지 10억 607만 달러에 달할 것으로 예상됩니다. 2026년부터 2033년까지 CAGR 4.8%로 성장할 것으로 전망됩니다.
| 보고서 범위 | 보고서 상세 | ||
|---|---|---|---|
| 기준 연도: | 2025년 | 2026년 시장 규모: | 7억 2,460만 달러 |
| 과거 데이터 기간: | 2020-2024년 | 예측 기간: | 2026-2033년 |
| 2026년부터 2033년까지 예측 기간 CAGR: | 4.80% | 2033년 시장 규모 예측: | 10억 607만 달러 |
세계 주기성 발열(PF) 시장은 희귀질환 치료제 분야의 전문 부문을 구성하고 있으며, 발열과 염증의 재발을 특징으로 하는 유전성 자가염증 증후군에 초점을 맞추고 있습니다. 가족성 지중해열(FMF), 종양괴사인자 수용체 관련 주기성 증후군(TRAPS), 크리오필린 관련 주기성 증후군(CAPS)을 포함한 이들 질환은 전 세계 수천 명의 환자에게 영향을 미치는 유전성 질환군입니다.
이 시장은 진단 능력의 향상, 질병의 병태생리에 대한 이해의 심화, 표적 치료제 개발에 힘입어 최근 몇 년 동안 괄목할 만한 진전을 이루었습니다. 제약회사와 생명공학 기업들은 이 환자군의 큰 미충족 수요를 충족시키기 위해 연구개발 활동에 대한 투자를 점점 더 확대하고 있습니다.
이 시장에는 항염증제, 생물학적 제제 및 주기성 발열(PF) 발작의 빈도와 심각성을 예방하거나 완화하는 것을 목표로 하는 새로운 표적 치료법 등 다양한 치료법이 포함되어 있습니다. 의료진의 인식이 높아지고 진단 기술이 향상됨에 따라 더 많은 환자들이 정확한 진단과 적절한 치료를 받을 수 있게 되면서 시장은 꾸준히 성장하고 있습니다. 그 결과, 이러한 쇠약성 자가 염증성 질환을 앓고 있는 사람들의 삶의 질이 궁극적으로 개선되고 있습니다.
시장 역학
세계 주기성 발열(PF) 시장은 주로 성장 궤도와 시장 침투를 계속 형성하는 몇 가지 강력한 요인에 의해 주도되고 있습니다. 전 세계적으로 유전성 자가염증증후군의 유병률 증가와 인식 개선은 기본적인 성장 요인으로 작용하고 있습니다. 이는 첨단 유전자 검사 및 바이오마커 식별 기술을 통해 그동안 충분히 인지하지 못했던 이러한 질병을 헬스케어 시스템이 보다 정밀하게 진단할 수 있게 되었기 때문입니다. 표적 생물학적 제제 및 정밀의료 접근법의 개발은 치료 패러다임에 혁명을 가져왔으며, 기존 항염증 치료와 비교하여 안전성 프로파일이 개선되어 환자들에게 보다 효과적인 치료 옵션을 제공하고 있습니다.
신속한 승인 절차, 시장 독점권 인센티브 등 희귀질환 치료제(희귀의약품) 개발에 대한 정부의 노력과 규제적 지원은 이 틈새 치료 분야에 대한 제약사의 투자를 촉진하고 있습니다. 그러나 시장에는 심각한 제약도 존재합니다. 특히 생물학적 제제 치료의 경우, 특히 개발도상국에서는 환자 및 의료 시스템에서 매우 높은 비용으로 인해 접근성에 대한 장벽이 되고 있습니다. 일차 진료 의사들 사이에서 질병에 대한 인식이 제한적이기 때문에 진단이 늦어지고 환자의 고통이 장기화되는 경우가 많습니다. 한편, 희귀질환에 내재된 환자 수가 적다는 것은 투자수익을 추구하는 제약사에게 상업적 도전이 되고 있습니다.
이러한 유전성 질환의 복잡성과 임상 증상의 다양성은 진단과 치료에 있어 또 다른 도전과제를 야기하고 있습니다. 그럼에도 불구하고, 세계 헬스케어 인프라의 확대, 신흥시장의 의료비 증가, 희귀질환 포트폴리오에 대한 제약 업계의 관심 증가로 인해 큰 기회가 존재합니다. 병용요법의 가능성, 유전자 프로파일링에 기반한 맞춤형 치료 접근법, 효능을 높이고 부작용을 줄인 차세대 치료제의 개발은 환자 결과와 시장 역학을 변화시킬 수 있는 중요한 시장 확대 기회를 의미합니다.
본 조사의 주요 특징
- 세계의 주기성 발열(PF) 시장에 대해 조사분석했으며, 2025년을 기준 연도로 하여 예측 기간(2026-2033년)의 시장 규모와 연평균 성장률(CAGR)을 조사하여 전해드립니다.
- 이 보고서는 각 부문의 잠재적 수익 기회를 밝히고, 이 시장에서 매력적인 투자 제안 매트릭스를 설명합니다.
- 또한 시장 촉진요인, 억제요인, 기회, 신제품 출시 및 승인, 시장 동향, 지역별 전망, 주요 기업의 경쟁 전략에 대한 중요한 인사이트도 제공합니다.
- 이 보고서는 다음과 같은 매개 변수를 기반으로 세계 주기성 발열(PF) 시장의 주요 업체를 프로파일링합니다. 구체적으로 기업 개요, 제품 포트폴리오, 주요 하이라이트, 재무 실적 및 전략 등입니다.
- 이 보고서의 내용을 통해 기업의 마케팅 담당자와 경영진은 향후 제품 출시, 제품 업그레이드, 시장 확대, 마케팅 전략에 대한 정보에 입각한 의사결정을 내릴 수 있을 것입니다.
- 이 보고서는 투자자, 공급업체, 제품 제조업체, 유통업체, 신규 진입자, 금융 분석가 등 이 업계의 다양한 이해관계자를 대상으로 합니다.
- 이해관계자들은 세계 주기성 발열(PF) 시장 분석에 사용되는 다양한 전략 매트릭스를 통해 의사결정을 쉽게 내릴 수 있을 것입니다.
목차
제1장 조사 목적과 가정
제2장 시장 범위
제3장 시장 역학, 규제 및 동향 분석
제4장 세계의 주기성 발열(PF) 시장 : 질환 유형별, 2021-2033년
제5장 세계의 주기성 발열(PF) 시장 : 치료 유형별, 2021-2033년
제6장 세계의 주기성 발열(PF) 시장 : 투여 경로별, 2021-2033년
제7장 세계의 주기성 발열(PF) 시장 : 진단 유형별, 2021-2033년
제8장 세계의 주기성 발열(PF) 시장 : 환자 그룹별, 2021-2033년
제9장 세계의 주기성 발열(PF) 시장 : 최종사용자별, 2021-2033년
제10장 세계의 주기성 발열(PF) 시장 : 유통 채널별, 2021-2033년
제11장 세계의 주기성 발열(PF) 시장 : 지역별, 2021-2033년
제12장 경쟁 구도
제13장 애널리스트의 추천
제14장 참고문헌 및 조사 방법
KSM 26.04.15Periodic Fever Market is estimated to be valued at USD 724.6 Mn in 2026 and is expected to reach USD 1,006.07 Mn by 2033, growing at a compound annual growth rate (CAGR) of 4.8% from 2026 to 2033.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2025 | Market Size in 2026: | USD 724.6 Mn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2026 To 2033 |
| Forecast Period 2026 to 2033 CAGR: | 4.80% | 2033 Value Projection: | USD 1,006.07 Mn |
The global periodic fever market encompasses a specialized segment of the rare disease therapeutics landscape, focusing on hereditary autoinflammatory syndromes characterized by recurrent episodes of fever and inflammation. These conditions, including Familial Mediterranean Fever (FMF), Tumor Necrosis Factor Receptor Associated Periodic Syndrome (TRAPS), and Cryopyrin-Associated Periodic Syndromes (CAPS), represent a group of genetically inherited disorders affecting thousands of patients worldwide.
The market has witnessed significant advancement in recent years, driven by enhanced diagnostic capabilities, improved understanding of disease pathophysiology, and the development of targeted therapeutic interventions. Pharmaceutical companies and biotechnology firms are increasingly investing in research and development activities to address the substantial unmet medical needs within this patient population.
The market encompasses various treatment modalities, including anti-inflammatory agents, biologics, and novel targeted therapies designed to prevent or reduce the frequency and severity of periodic fever episodes. With growing awareness among healthcare professionals and improved diagnostic techniques, the market is experiencing steady expansion as more patients receive accurate diagnoses and appropriate treatment interventions, ultimately improving quality of life outcomes for individuals suffering from these debilitating autoinflammatory conditions.
Market Dynamics
The global periodic fever market is primarily driven by several compelling factors that continue to shape its growth trajectory and market penetration. The increasing prevalence and recognition of hereditary autoinflammatory syndromes worldwide serves as a fundamental growth driver, as healthcare systems become more sophisticated in diagnosing these previously under-recognized conditions through advanced genetic testing and biomarker identification technologies. The development of targeted biologics and precision medicine approaches has revolutionized treatment paradigms, offering patients more effective therapeutic options with improved safety profiles compared to traditional anti-inflammatory treatments.
Government initiatives and regulatory support for orphan drug development, including expedited approval pathways and market exclusivity incentives, have encouraged pharmaceutical investments in this niche therapeutic area. However, the market faces significant restraints including the extremely high costs associated with biologic therapies, which create accessibility barriers for patients and healthcare systems, particularly in developing economies. Limited disease awareness among primary care physicians often leads to delayed diagnoses and prolonged patient suffering, while the small patient populations inherent to rare diseases present commercial challenges for pharmaceutical companies seeking return on investment.
The complexity of these genetic disorders and variability in clinical presentations create additional diagnostic and treatment challenges. Nevertheless, substantial opportunities exist through expanding global healthcare infrastructure, increasing healthcare expenditure in emerging markets, and growing pharmaceutical industry focus on rare disease portfolios. The potential for combination therapies, personalized treatment approaches based on genetic profiling, and the development of next-generation therapeutics with improved efficacy and reduced side effect profiles represent significant market expansion opportunities that could transform patient outcomes and market dynamics.
Key Features of the Study
- This report provides in-depth analysis of the global Periodic Fever market, and provides market size (USD Mn) and compound annual growth rate (CAGR%) for the forecast period (2026-2033), considering 2025 as the base year
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global periodic fever market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
- Key companies covered as a part of this study include Novartis, Swedish Orphan Biovitrum Sobi, Regeneron Pharmaceuticals, Takeda Pharmaceutical Company, Hikma Pharmaceuticals, Amgen, Pfizer, AbbVie, Janssen Biotech Johnson and Johnson, Roche, Sanofi, UCB, Bristol Myers Squibb, Teva Pharmaceutical Industries, and Dr Reddys Laboratories
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
- The global periodic fever market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global periodic fever market
Market Segmentation
- Disease Type Insights (Revenue, USD Mn, 2021 - 2033)
- Familial Mediterranean Fever
- TNF Receptor-Associated Periodic Syndrome
- Mevalonate Kinase Deficiency
- Cryopyrin-Associated Periodic Syndromes
- PFAPA Syndrome
- Systemic Autoinflammatory Periodic Fevers
- Treatment Type Insights (Revenue, USD Mn, 2021 - 2033)
- Biologic Therapies
- Corticosteroids
- Colchicine Therapy
- NSAIDs & Symptomatic Treatments
- Immunosuppressants
- Emerging Targeted Therapies & Gene-based Treatments
- Route of Administration Insights (Revenue, USD Mn, 2021 - 2033)
- Injectable
- Oral
- Intravenous Infusion
- Diagnosis Type Insights (Revenue, USD Mn, 2021 - 2033)
- Genetic Testing
- Laboratory & Biomarker Testing
- Clinical Diagnosis
- Imaging & Supportive Diagnostic Methods
- Patient Group Insights (Revenue, USD Mn, 2021 - 2033)
- Pediatric Patients
- Adult Patients
- End User Insights (Revenue, USD Mn, 2021 - 2033)
- Hospitals
- Specialty & Rheumatology Clinics
- Ambulatory Surgical Centers
- Homecare Settings
- Distribution Channel Insights (Revenue, USD Mn, 2021 - 2033)
- Online
- Offline
- Regional Insights (Revenue, USD Mn, 2021 - 2033)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
- Key Players Insights
- Novartis
- Swedish Orphan Biovitrum Sobi
- Regeneron Pharmaceuticals
- Takeda Pharmaceutical Company
- Hikma Pharmaceuticals
- Amgen
- Pfizer
- AbbVie
- Janssen Biotech Johnson and Johnson
- Roche
- Sanofi
- UCB
- Bristol Myers Squibb
- Teva Pharmaceutical Industries
- Dr Reddys Laboratories
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Global Periodic Fever Market, By Disease Type
- Global Periodic Fever Market, By Treatment Type
- Global Periodic Fever Market, By Route of Administration
- Global Periodic Fever Market, By Diagnosis Type
- Global Periodic Fever Market, By Patient Group
- Global Periodic Fever Market, By End User
- Global Periodic Fever Market, By Distribution Channel
- Global Periodic Fever Market, By Region
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Impact Analysis
- Key Highlights
- Regulatory Scenario
- Product Launches/Approvals
- PEST Analysis
- PORTER's Analysis
- Market Opportunities
- Regulatory Scenario
- Key Developments
- Industry Trends
4. Global Periodic Fever Market, By Disease Type, 2021-2033, (USD Mn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Familial Mediterranean Fever
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
- TNF Receptor-Associated Periodic Syndrome
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
- Mevalonate Kinase Deficiency
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
- Cryopyrin-Associated Periodic Syndromes
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
- PFAPA Syndrome
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
- Systemic Autoinflammatory Periodic Fevers
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
5. Global Periodic Fever Market, By Treatment Type, 2021-2033, (USD Mn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Biologic Therapies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
- Corticosteroids
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
- Colchicine Therapy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
- NSAIDs & Symptomatic Treatments
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
- Immunosuppressants
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
- Emerging Targeted Therapies & Gene-based Treatments
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
6. Global Periodic Fever Market, By Route of Administration, 2021-2033, (USD Mn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Injectable
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
- Oral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
- Intravenous Infusion
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
7. Global Periodic Fever Market, By Diagnosis Type, 2021-2033, (USD Mn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Genetic Testing
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
- Laboratory & Biomarker Testing
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
- Clinical Diagnosis
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
- Imaging & Supportive Diagnostic Methods
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
8. Global Periodic Fever Market, By Patient Group, 2021-2033, (USD Mn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Pediatric Patients
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
- Adult Patients
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
9. Global Periodic Fever Market, By End User, 2021-2033, (USD Mn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Hospitals
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
- Specialty & Rheumatology Clinics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
- Ambulatory Surgical Centers
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
- Homecare Settings
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
10. Global Periodic Fever Market, By Distribution Channel, 2021-2033, (USD Mn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Online
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
- Offline
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
11. Global Periodic Fever Market, By Region, 2021 - 2033, Value (USD Mn)
- Introduction
- Market Share (%) Analysis, 2026, 2029 & 2033, Value (USD Mn)
- Market Y-o-Y Growth Analysis (%), 2022 - 2033, Value (USD Mn)
- Regional Trends
- North America
- Introduction
- Market Size and Forecast, By Disease Type, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Treatment Type, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Diagnosis Type, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Patient Group, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By End User, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Mn)
- U.S.
- Canada
- Latin America
- Introduction
- Market Size and Forecast, By Disease Type, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Treatment Type, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Diagnosis Type, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Patient Group, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By End User, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Mn)
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Introduction
- Market Size and Forecast, By Disease Type, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Treatment Type, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Diagnosis Type, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Patient Group, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By End User, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Mn)
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, By Disease Type, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Treatment Type, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Diagnosis Type, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Patient Group, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By End User, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Mn)
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- Introduction
- Market Size and Forecast, By Disease Type, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Treatment Type, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Diagnosis Type, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Patient Group, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By End User, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Mn)
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, By Disease Type, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Treatment Type, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Diagnosis Type, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Patient Group, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By End User, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Country/Region, 2021 - 2033, Value (USD Mn)
- South Africa
- North Africa
- Central Africa
12. Competitive Landscape
- Novartis
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Swedish Orphan Biovitrum Sobi
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Regeneron Pharmaceuticals
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Takeda Pharmaceutical Company
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Hikma Pharmaceuticals
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Amgen
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Pfizer
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- AbbVie
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Janssen Biotech Johnson and Johnson
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Roche
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Sanofi
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- UCB
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Bristol Myers Squibb
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Teva Pharmaceutical Industries
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Dr Reddys Laboratories
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
13. Analyst Recommendations
- Wheel of Fortune
- Analyst View
- Coherent Opportunity Map
14. References and Research Methodology
- References
- Research Methodology
- About us
